Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
Technology appraisal guidance
Reference number: TA914
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.